Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SIDI Group Expects "Passport" To Business Growth With Standardized CofA

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement ingredient suppliers should approach standardizing information in their certificates of analysis as an investment that will pay off in business growth, say industry stakeholders who wrote a CofA guideline

You may also be interested in...



SIDI Group Split Reflects Supplement Industry Disparate Interests

The Standardized Information on Dietary Ingredients working group loses the American Herbal Products and the Natural Products associations as members, while three other trade groups continue developing best practices for qualifying supplement ingredient suppliers

SIDI Group Split Reflects Supplement Industry Disparate Interests

The Standardized Information on Dietary Ingredients working group loses the American Herbal Products and the Natural Products associations as members, while three other trade groups continue developing best practices for qualifying supplement ingredient suppliers

As Supplement GMP Implementation Hits Zero Hour, Small Firms Still Struggle

FDA's final rule for dietary supplement good manufacturing practices completed its phase-in for the industry June 25, and the agency now prepares to conduct inspections of small firms, which have struggled the most to comply with the regulation

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel